Literature DB >> 24384834

The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Masaki Terabe1, Jay A Berzofsky.   

Abstract

NKT cells are CD1d-restricted T cells that recognize lipid antigens. They also have been shown to play critical roles in the regulation of immune responses. In the immune responses against tumors, two subsets of NKT cells, type I and type II, play opposing roles and cross-regulate each other. As members of both the innate and adaptive immune systems, which form a network of multiple components, they also interact with other immune components. Here, we discuss the function of NKT cells in tumor immunity and their interaction with other regulatory cells, especially CD4(+)CD25(+)Foxp3(+) regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384834      PMCID: PMC4012252          DOI: 10.1007/s00262-013-1509-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  120 in total

1.  Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization.

Authors:  Karin Roelofs-Haarhuis; Xianzhu Wu; Michael Nowak; Min Fang; Suzan Artik; Ernst Gleichmann
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

2.  Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells.

Authors:  Alexandre Darmoise; Susann Teneberg; Lauriane Bouzonville; Roscoe O Brady; Michael Beck; Stefan H E Kaufmann; Florian Winau
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

3.  Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo.

Authors:  Gourapura J Renukaradhya; Venkataraman Sriram; Wenjun Du; Jacquelyn Gervay-Hague; Luc Van Kaer; Randy R Brutkiewicz
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

4.  NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Authors:  Stephen R Mattarollo; Alison C West; Kim Steegh; Helene Duret; Christophe Paget; Ben Martin; Geoffrey M Matthews; Jake Shortt; Marta Chesi; P Leif Bergsagel; Michael Bots; Johannes Zuber; Scott W Lowe; Ricky W Johnstone; Mark J Smyth
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

5.  Natural killer cells determine the outcome of B cell-mediated autoimmunity.

Authors:  F D Shi; H B Wang; H Li; S Hong; M Taniguchi; H Link; L Van Kaer; H G Ljunggren
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

6.  CD1d-specific NK1.1+ T cells with a transgenic variant TCR.

Authors:  M Sköld; N N Faizunnessa; C R Wang; S Cardell
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

7.  Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.

Authors:  Stephen R Mattarollo; Kim Steegh; Ming Li; Helene Duret; Shin Foong Ngiow; Mark J Smyth
Journal:  Immunol Cell Biol       Date:  2012-10-23       Impact factor: 5.126

8.  Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells.

Authors:  Nadia Duarte; Martin Stenström; Susana Campino; Marie-Louise Bergman; Marie Lundholm; Dan Holmberg; Susanna L Cardell
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

9.  iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.

Authors:  Matteo Bellone; Monica Ceccon; Matteo Grioni; Elena Jachetti; Arianna Calcinotto; Anna Napolitano; Massimo Freschi; Giulia Casorati; Paolo Dellabona
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

10.  Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation.

Authors:  Dale Christiansen; Julie Milland; Effie Mouhtouris; Hilary Vaughan; Daniel G Pellicci; Malcolm J McConville; Dale I Godfrey; Mauro S Sandrin
Journal:  PLoS Biol       Date:  2008-07-15       Impact factor: 8.029

View more
  39 in total

Review 1.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 2.  The Alpha and Omega of Galactosylceramides in T Cell Immune Function.

Authors:  Alysia M Birkholz; Amy R Howell; Mitchell Kronenberg
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

Review 3.  Role and regulation of CD1d in normal and pathological B cells.

Authors:  Mohammed S Chaudhry; Anastasios Karadimitris
Journal:  J Immunol       Date:  2014-11-15       Impact factor: 5.422

4.  Differential dependence on nuclear factor-κB-inducing kinase among natural killer T-cell subsets in their development.

Authors:  Haruka Noma; Koji Eshima; Masashi Satoh; Kazuya Iwabuchi
Journal:  Immunology       Date:  2015-06-25       Impact factor: 7.397

5.  Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.

Authors:  Irina V Tiper; Tonya J Webb
Journal:  Cancer Immunol Immunother       Date:  2016-09-10       Impact factor: 6.968

6.  Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.

Authors:  Tonya J Webb; Gregory B Carey; James E East; Wenji Sun; Dominique R Bollino; Amy S Kimball; Randy R Brutkiewicz
Journal:  Pathog Dis       Date:  2016-06-12       Impact factor: 3.166

7.  All-trans-retinoic acid and CD38 ligation differentially regulate CD1d expression and α-galactosylceramide-induced immune responses.

Authors:  Qiuyan Chen; A Catharine Ross
Journal:  Immunobiology       Date:  2014-09-16       Impact factor: 3.144

8.  Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway.

Authors:  Priyanka B Subrahmanyam; Gregory B Carey; Tonya J Webb
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

9.  Critical role of NKT cells in posttransplant alloantibody production.

Authors:  J M Zimmerer; P Swamy; P B Sanghavi; C L Wright; M Abdel-Rasoul; S M Elzein; R R Brutkiewicz; G L Bumgardner
Journal:  Am J Transplant       Date:  2014-09-12       Impact factor: 8.086

Review 10.  Targeting Natural Killer T Cells in Solid Malignancies.

Authors:  Zewde Ingram; Shriya Madan; Jenoy Merchant; Zakiya Carter; Zen Gordon; Gregory Carey; Tonya J Webb
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.